← Back to Search

Biopsy Cohort for Cancer (PanGen Trial)

N/A
Recruiting
Led By Daniel J Renouf, MD
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.

Eligible Conditions
  • Cancer
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of days between biopsy and return of comprehensive genomic results.
Secondary study objectives
Disease Control Rate
Duration of Response
Overall Survival
+2 more
Other study objectives
DNA damage repair pathways
Hypermutated phenotype
Mismatch repair deficiency
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Biopsy CohortExperimental Treatment2 Interventions
Participants will undergo a tumour biopsy at baseline and an optional tumour biopsy at disease progression. Participants will undergo serial collection of plasma and serum samples.
Group II: Archival CohortExperimental Treatment1 Intervention
Genomic analyses will be performed on participants' archival tumour samples. Participants will undergo serial collection of plasma and serum samples.

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
175 Previous Clinical Trials
94,038 Total Patients Enrolled
Terry Fox Research InstituteOTHER
10 Previous Clinical Trials
1,378 Total Patients Enrolled
BC Cancer FoundationOTHER
18 Previous Clinical Trials
8,369 Total Patients Enrolled
~38 spots leftby Dec 2026